Matarin Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Matarin Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-316,858	Closed	-$5.33M	–	315
2018 Q2	$5.33M	Buy	316,858 +31,408	+11%	+$610K	0.39%	93
2018 Q1	$6.54M	Buy	285,450 +137,237	+93%	+$3.05M	0.49%	76
2017 Q4	$3.83M	Buy	+148,213	New	+$2.98M	0.3%	128

Other funds holding CNCE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Matarin Capital Management's CNCE Position: Q3 2018 in Review

Matarin Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 316,858 shares — an estimated $5.33M sold.

Matarin Capital Management first reported a position in CNCE in Q4 2017 and held it in 3 quarters. The position peaked at $6.54M in Q1 2018. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

Matarin Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Matarin Capital Management sold 316,858 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $5.33M.
Matarin Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
Matarin Capital Management's Concert Pharmaceuticals, Inc. position peaked at $6.54M in Q1 2018.
111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Matarin Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.